TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Chronic Otitis Media Questionnaire 12 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive Koebner Phenomena (K+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative Koebner Phenomena (K-)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in pruritus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myelination of the white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline esophageal 24 hour pH/impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline symptoms of gastroesophageal reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse events during the study period
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HIV incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in STI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in relationship communication patterns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to the training program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in oral reading accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in social engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in sibling relationship
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With One or More Unsolicited Non-Serious Adverse Events Following L9LS Product Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Peripapillary and macular vascular changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Regional renal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour weighed mean glucose (WMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Virologic failure at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in peripheral immune biomarkers associated with inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes from baseline in emotion regulation assessed with the Difficulty in Emotion Regulation Scale (DERS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of TLC-2716 treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Strength Test with Lafayette Hand Held Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception Measurement with Baseline Bubble Inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time without pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Liver function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model for end-stage liver disease score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negative nucleic acid and antigen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of GER episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of GER episodes reaching the proximal esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time with pH<4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Description of symptoms attributed to COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mitral regurgitant volume (RVol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mitral regurgitant fraction (RF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite adverse maternal and perinatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the Motor Function Measure-32 (MFM-32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Manual Muscle Testing (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Hand-Held dynamometry (HHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Pinch and Grip test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Intraoperative Acquired Pressure Injuries (IAPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participant With Erythema, Abrasions, and Moisture Associated Skin Damage (MASD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With a (Sub-epidermal Moisture) SEM Scanner Difference of Greater Than 0.5pF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: prevalence of injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in sputum Acetylated Proline-Glycine-Proline (AcPGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of coagulation as measured by platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of coagulation as measured by thrombin-antithrombin (TAT) complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of fibrinolysis as measured by plasmin-antiplasmin complex (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of fibrinolysis as measured by D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of inflammation as measured by C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consolidation Area Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Flow Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort-Expenditure for Rewards Task (EEfRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify Mental States
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drinking over time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: upper extremity proprioseption test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kinesthesia Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Jebsen Taylor Hand Function Test (JTHFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DVT incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: PE incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence rate of vaccination-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to progression of pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to recurrence of lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PROMIS Global health v1.2 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sinonasal Outcomes Test (SNOT)-22 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rhinosinusitis Disability Index (RSDI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mini-RQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of infusion-related reactions (IRR) and hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin Scale (mRS) scores of 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate pleural space evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rhinoconjunctivitis-related quality of life questionnaire (RQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of manual pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmorphic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of identifying atypical neurofibromas and related lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: One Year Invasive Disease-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Adverse effects self-management measurement
Endpoint domain: Adverse events/effects
Primary endpoint: Change in European Quality of Life-Five Dimensions (EQ-5D) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in RAND 36-Item short form health-related quality of life survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (CCQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of local and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (GC) detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Modified Rankin Scale
Endpoint domain: Mortality/survival
Primary endpoint: MIP assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Women's specific needs and expectations for pregnancy follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of affective disorders at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anxiety disorders at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of eating disorders at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms: incidence at 24-month FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms: recovery at 24-month FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety symptoms: incidence at 24-month FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPDS score as a continuous outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EPDS score of 13 or more at 2-months postpartum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Midfacial Gingival Margin Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who consent for enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with Primary Aldosteronism (PA) that were missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Positive for Respiratory Syncytial Virus (RSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Positive for Influenza Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with Relative Risk of Acute Respiratory Infections (ARI)- related Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerance of sesame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index (HEI)-2015 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in plasma IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in plasma Neurofilament light levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of cancer-associated venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relapse-free survival (RFS) time
Endpoint domain: Mortality/survival
Primary endpoint: Consciousness outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of products successfully manufactured and infused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actigraphy-derived sleep indicators
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Dim-light melatonin onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the SI!-Child health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC of LYT-100 and nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of resolution of cSDH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Number of clinically significant non-hematologic grade 3 or 4 treatment-related AEs or hematologic grade 3 or 4 treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Progression free survival (PFS) assessed by Lugano criteria
Endpoint domain: Mortality/survival
Primary endpoint: Subclinical atherosclerosis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in MADRS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of vessel transections with an achievement of Grade 3 or lower
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Device-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Restoration of ureteric patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Delta change in Psychometric Hepatic Encephalopathy Score (PHES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Day of life to reach full feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Kidney Event 90 days after randomization
Endpoint domain: Adverse events/effects
Primary endpoint: respiratory microbiome and biogenics profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum concentration of SHBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum concentration of CTX-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentration of CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in parenting (Impact scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Min Walk Distance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reverse torque test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t½z)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve for the elimination phase (AUCelim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Retention Data
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Drug Use Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants receiving a lung ultrasound within 6 hours of admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Damaged platelet mitochondrial bioenergetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous coenzyme Q10-TOTAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of inflammatory episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Relaxation Sum Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in performance on the Oxford Multiple Errands Test- Dutch version (OxMET-NL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraocular pressure elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of resolution of Tubal Ectopic Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percent Change from Baseline in Lipoprotein (a) Lp(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of CLL patients that require treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abundance of individual bacterial taxa in the gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relationship between changes in the gut microbiome induced by EPA and survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Effect of human faecal samples on tumour burden in gnotobiotic mice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of new thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of all thrombotic complications after anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of nurses' use of family centered care practices
Endpoint domain: Delivery of care
Primary endpoint: Change in Asthma Control Questionnaire 5 (ACQ-5) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in post- broncodilator Forced Expiratory Volume after 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absence of exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Use rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean weight-for-height/length z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of adverse events (pneumothorax, pocket hematoma, arterial puncture, pocket or device infection, hemothorax)
Endpoint domain: Adverse events/effects
Primary endpoint: Urine sediment abnormalities (proteinuria, creatininuria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in Usable ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in RR intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Max CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Sum CTCAE score
Endpoint domain: Adverse events/effects